FASTBASE SOLUTIONS offer tailor-made prevention and treatment strategies for individuals!

By matching patients to the optimum available treatment for their needs we can reduce issues associated with the application of incorrect treatments, reduce time wasted administering ineffective treatments to patients and deliver a higher quality of life to patients.

FASTBASE SOLUTIONS’ objective is to bring a new vision to the diagnostic/prognosis of cancer using quantitative biology to objectively increase precision, thereby, enabling a precision patient treatment through the use of more thorough and specific cancer prognosis. In the EU alone, national health systems spend about €124bn per year on health services for cancer patients with less than 15% of patients surviving after 5 years.

FASTBASE SOLUTIONS imaging system, is composed of a proprietary adapted microscope powered by software based on a proprietary time-resolved Amplified FRET technique. It determines both molecular and cell-cell interactions, enabling the evaluation of clinical efficiency of personalised cancer treatments.

Direct treatment is provided for those patients that respond to the more accurate diagnosis.

High-throughput quantification of Protein Kinase B
activation (PKB/Akt) in human breast Tissue
MicroArray (TMA) using FASTBASE Technology

Immunohistochemistry staining (H&E staining) of breast TMAs prepared from breast tumour biopsies.

#

Intensity images (black and white) and lifetime maps (pseudo colours) of the TMAs stained with panAkt +(panAkt+pT308), followed by A-FRET. TMAs were mapped and images automatically acquired using our FASTBASE platform. Adapted from Veeriah et al 2014, Cancer Research

#

Our Mission

To be a leading platform in cancer diagnostics and prognosis, bringing precision to patient treatment.

Our Vision

FASTBASE SOLUTIONS’ objective is to be a new vision in the diagnostic/prognosis of cancer using quantitative biology for objectively increasing precision.

Indiscriminate lengthy use of chemotherapies

Chemotherapy has proven to be a lengthy and extensive treatment for cancer patients and is associated with a high life-threatening risk to patients!

Unreliable prognostics and Limited precision with linking patient to therapy

30% of current techniques used to identify biomarkers lack sensitivity and precision resulting in poor patient prognosis!

High costs and poor efficiency of treatment

In the EU alone, national health systems spent about €124bn per year on health services for cancer patients with less than 15% of patients surviving after 5 years.

Lower quality of patient life

Patients are often missing the opportunity to have the most effective treatment for their illness and as a result have a lower quality of life.

Our Assets

FASTBASE SOLUTIONS offer a precision patient treatment through the use of more thorough and specific cancer prognosis.

Technology

FASTBASE SOLUTIONS is an imaging system, composed of a proprietary adapted microscope powered by software based on a proprietary time-resolved A-FRET technique. It determines both molecular and cell-cell interactions, enabling the evaluation of clinical efficiency of personalised cancer treatments.

Benefits of FASTBASE SOLUTIONS

Better response to treatment

Patients are better predicted to respond to targeted therapeutics leading to a higher chance of survival and quality of life

Direct treatment

Direct treatment is made to those patients that respond to the diagnosis

Lower drug costs

Reduction in drug costs as the right treatment is applied the first time around